A real-life cohort study assessing treatment of multiple sclerosis with natalizumab
Latest Information Update: 16 Dec 2021
Price :
$35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2021 New trial record